Last reviewed · How we verify
Citomix (BINETRAKIN)
At a glance
| Generic name | BINETRAKIN |
|---|---|
| Sponsor | Guna spa |
| Drug class | Lymphocyte Growth Factor [EPC] |
| Modality | Recombinant protein |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Seasonal colds
Common side effects
Key clinical trials
- Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis (PHASE2)
- Pro- and Anti-inflammatory Cytokines in PCOS
- Dupilumab Effects Against Aeroallergen Challenge (PHASE2)
- Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis (PHASE3)
- Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis (PHASE1,PHASE2)
- Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents (PHASE2)
- Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis (PHASE3)
- Study of CM310 in Adolescent Subjects With Atopic Dermatis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Citomix CI brief — competitive landscape report
- Citomix updates RSS · CI watch RSS
- Guna spa portfolio CI